Kiniksa Pharmaceuticals International Plc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kiniksa Pharmaceuticals International Plc's ROA in the first quarter of 2026?
Kiniksa Pharmaceuticals International Plc achieved a return on average assets (ROA) of 9.86 % in its first quarter of 2026, this is above KNSA's average return on assets of -17.82%.
Kiniksa Pharmaceuticals International Plc assets over the 12 months ending in its first quarter of 2026 are valued at $741 million

ROA has improved compared to 8.63% in the fourth quarter of 2025, due to net income growth.

However, within the Healthcare sector 98 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 615, from total ROA ranking in the fourth quarter of 2025 at 835.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	37.7 %	105.99 %	103.9 %	94.8 %	95.66 %
Y / Y Net Income Change	164.57 %	-	-	-	-
Net Income (TTM) in million	73	59	36	5	-17
Return On Assets (TTM)	9.86 %	8.63 %	6.13 %	0.97 %	-4.09 %
KNSA's Total Ranking	# 615	# 835	# 1082	# 2267	# 2926
Total Assets (TTM) in million	825	764	712	661	599
Seq. Total Assets Change	8.07 %	7.2 %	7.74 %	10.32 %	61.67 %
Seq. Net Income Change	59.11 %	-22.98 %	3.38 %	108.83 %	-

KNSA's 5 Years Annual ROA >> Back to KNSA Management Effectiveness >> Compare KNSA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 40
Sector	# 99
Overall	# 609

Return On Assets Statistics
High	Average	Low
53.88 %	-17.82 %	-70.21 %
(Dec 31 2022)		(Sep 30 2019)

Financial Statements
Kiniksa Pharmaceuticals International Plc's Assets	$ 825 million	KNSA's Balance sheet
Kiniksa Pharmaceuticals International Plc's Income	$ 23 million	Quarterly KNSA's Income Statement
KNSA's Income by Division		See KNSA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	105.99 %	20.25 %	12.12 %	18.11 %	-33.35 %
Total Assets in million	764	371	308	275	233
Y / Y Net Income Change	-	-	-92.32 %	-	-
Net Income in million	59	-43	14	183	-158
Annual Return On Assets	7.73 %	-11.65 %	4.57 %	66.69 %	-67.84 %

KNSA's 5 Years Annual ROA >> Back to KNSA Management Effectiveness >> Compare KNSA ROA to its Competitors

Comment on KNSA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 7.73 % compared to prior year, due to annual net income growth of % to $59.01 million, while value of Kiniksa Pharmaceuticals International Plc's overall assets grew just by 105.99 % to $763.63 million, compared to $763.63 a year before.

More Return On Assets Ratios
KNSA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KNSA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KNSA's Competitors
Subscribers only: Roa for Kiniksa Pharmaceuticals International Plc's Suppliers
Subscribers only: Return On Assets for KNSA's Customers

You may also want to know
KNSA's Roi	KNSA's Inventory Turnover Ratio	KNSA's Growth Rates	KNSA's Dividend Comparisons
	KNSA's Profitability Ratios	KNSA's Asset Turnover Ratio	KNSA's Dividend Growth
KNSA's Roe	KNSA's Valuation Ratios	KNSA's Financial Strength Ratios	KNSA's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector	ROA
Rafael Holdings Inc	26.85 %
Acadia Pharmaceuticals Inc	26.24 %
Ironwood Pharmaceuticals inc	26.02 %
Theravance Biopharma inc	25.46 %
Spero Therapeutics Inc	24.95 %
Medpace Holdings Inc	24.79 %
Mettler toledo International Inc	24.47 %
Qhslab Inc	23.09 %
Eli Lilly And Company	22.73 %
Incyte Corporation	21.65 %
Iradimed Corporation	21.25 %
Catalyst Pharmaceuticals Inc	20.71 %
Engene Therapeutics Inc	20.52 %
Vaxart Inc	20.07 %
Indivior Pharmaceuticals Inc	19.14 %
Pro dex Inc	18.35 %
Electromed Inc	18.31 %
Soleno Therapeutics Inc	18.25 %
Resmed Inc	18.18 %
Protalix Biotherapeutics inc	17.75 %
Krystal Biotech Inc	17.62 %
Zoetis Inc	17.60 %
United Therapeutics Corporation	17.25 %
Vertex Pharmaceuticals Inc	17.18 %
Chemed Corporation	16.20 %
Gilead Sciences Inc	16.06 %
Transmedics Group Inc	15.85 %
Inspire Medical Systems inc	15.30 %
Neurocrine Biosciences Inc	15.12 %
Strata Critical Medical Inc	15.09 %

Date modified: 2026-09-26T07:37:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.